

## CURRICULUM VITAE

W. JEFFREY FESSEL.

Email: jeffreyfessel@gmail.com

Phone Number: (415) 563 0818 (home)

### DEGREES AND DIPLOMAS

|      |   |
|------|---|
| 1954 | MB BS (University of London).                             |
| 1987 | Founding <u>Fellow</u> , American College of Rheumatology |
| 1971 | <u>Fellow</u> , Royal College of Physicians (Edinburgh)   |
| 1966 | <u>Fellow</u> , American College of Physicians            |
| 1965 | Diplomat of American Board of Internal Medicine           |

### BOARD ELIGIBLE

Rheumatology

### DISTINCTIONS

Foundation Scholar, St. Paul's School, London, England.

Liston Gold Medal, University College Hospital Medical School, London, England.

Listed in "Who's Who in America", 59th/60th/61st Editions, 2005-present (Marquis).

Listed in "Who's Who in the World", 22nd/23rd/24th Editions, 2005-present (Marquis).

Listed in "2000 Outstanding Intellectuals of the 21st Century" (International Biographical Centre).

Morris F Collen Research Award 2008.

### UNIVERSITY APPOINTMENTS

|              |   |
|--------------|---|
| 1996-Present | Emeritus Clinical Professor of Medicine, University of California, San Francisco    |
| 1983-1996    | Clinical Professor of Medicine, University of California, San Francisco, California |
| 1982-1988    | Associate Professor of Clinical Medicine, Stanford University, Stanford, California |

## **HOSPITAL APPOINTMENTS**

|                 |  |
|-----------------|--|
| 1990-Sept 2018. | Director, Clinical Trials Unit, Kaiser Permanente, San Francisco, California   |
| 1979-1989       | Chief of Medicine, Kaiser Foundation Hospital and Permanente Medical Center, San Francisco, California                 |
| 1979-1989       | Director of Internal Medicine Residency Training Program, Kaiser Foundation Hospital, San Francisco, California        |
| 1965-Sept 2018. | Rheumatologist and Staff Internist, Kaiser Foundation Hospital and Permanente Medical Group, San Francisco, California |

**EDITORIAL BOARD:** AIDS. 2012-2016.

**GUEST EDITOR:** for Journal of Clinical Medicine special issue “Drug treatment in Psychiatry: Progress and Challenges”, Jan-Sept 2023.

## **MANUSCRIPT AND BOOK REVIEWER FOR:**

AIDS

Alzheimer’s & Dementia.

American Journal of Epidemiology

American Journal of Medicine

American College of Physicians-American Society of Internal Medicine, Physicians Information and Education Resource

Annals of Internal Medicine

Antiviral Therapy

Archives of Internal Medicine

Arthritis and Rheumatism

Arthritis Care and Research

Brain

Chest

Clinical Infectious Disease

Heart and Lung

Houghton and Mifflin (Publishers)  
Journal of Acquired Immunodeficiency  
Journal of the American Medical Association  
Journal of Clinical Medicine  
Journal of Gerontology  
Journal of Rheumatology  
Metabolism  
Neurobiology of Aging.  
New England Journal of Medicine.  
Postgraduate Medicine.  
Western Journal of Medicine.

**Abstract reviewer for International AIDS Conferences; 2016,2017,2018, 2019, 2020, 2022**

**COMMITTEE SERVICE**

|                  |  |
|------------------|--|
| 1999-Sept 2018.  | Regional Pharmacy and Therapeutics Subcommittee, Regional AIDS Advisory Committee, Kaiser Permanente, N.Cal.   |
| 1986- Sept 2018. | Clinical Faculty Review Committee, Univ. California, San Francisco.  |
| 1980-1989        | <u>Chairman</u> , Regional Chiefs of Medicine, N. California Permanente Medical Group  |
| 1986-1989        | <u>Chairman (and founder)</u> , Committee on Health Care for the Homeless, San Francisco Medical Society<br><u>Past Chairman</u> , Research Committee, Kaiser Foundation Hospital, San Francisco<br><u>Past Chairman</u> , Medical Records Committee, Kaiser Foundation Hospital, San Francisco. |

## **VISITING LECTURER**

All India Medical Association Meeting, Bombay

Guy's Hospital, London

Hebrew University Medical School

Royal Postgraduate Medical School, London

Stanford University

State University of New York, Buffalo

University of Oklahoma

University of Taiwan

University of Tokyo

Numerous hospitals in San Francisco Bay Area

## **CONTINUING EDUCATION COURSES: Organizer and Chairman:**

|           |   |
|-----------|---|
| Nov. 1997 | “First Kaiser-Permanente National Symposium on HIV/AIDS”  |
| May 1988  | “A Symposium on Hyperlipidemia for the Practicing Internist”, San Francisco, California                     |
| Nov. 1987 | “Nephrology for the Practicing Internist”, San Francisco, California  |
| Mar. 1986 | “Tutorials in Medicine”, San Francisco, California  |
| Nov. 1983 | “A Symposium on Rheumatology for Generalists and Specialists”, San Francisco, California                    |
| Oct. 1982 | “Review of Internal Medicine”, Royal Postgraduate Medical School, London, England                           |
| Jul. 1982 | “Useful Cardiology for Clinical Practice”, San Francisco, California  |
| Dec. 1973 | “A Symposium on Rheumatic Diseases in Clinical Practice”, (Arthritis Foundation), San Francisco, California |
| Mar. 1967 | “The Change and Ferment of Rheumatology”, (Sponsored by Arthritis Foundation), San Francisco, California    |
| Speaker:  |   |
| Sept 2000 | “Kaiser Permanente HIV/AIDS Treatment Update”, San Francisco.   |

|               |  |
|---------------|--|
| 1999 and 1996 | “AIDS update” public television panel and call-in program San Francisco.   |
| June 1999     | “Role of efavirenz in treatment of HIV/AIDS”. Lecture given to two Infectious Disease Meetings, at Bangkok and Pattaya, Thailand.          |
| April 1999    | “Control of pain in the HIV patient”. Lecture to Drug Enforcement Administration Annual Meeting, San Francisco.                            |
| Oct. 1988     | Treasurer, Northern California Scientific Meeting American College of Physicians, Monterey, California.                                    |
| Sept. 1982    | “Arthritis Foundation, National Telethon”, Nashville, Tennessee.   |
| March 1982    | Keynote Speaker: “Rheumatology Update 1982”, (Arthritis Foundation and Wilmington Academy of Medicine Course), Wilmington, Delaware.       |
| April 1980    | “Current Concepts in the Surgical Management of Arthritic Problems”, (American Academy of Orthopedic Surgeons), San Francisco, California. |
| Dec. 1978     | “Caring for the Arthritis Patient”, (Univ. California Course), San Francisco, California.  |
| May 1978      | “Advances in Internal Medicine”, (Univ. California Course) San Francisco, California.  |
| Sept. 1977    | “Clinical Immunology/Arthritis Update”, (Univ. California Course), San Francisco, California.  |
| April 1977    | “Advances in Internal Medicine”, (Univ. California Course), San Francisco, California.   |
| March 1976    | “Basic Science Approach to Orthopedic Diseases” (American Academy of Orthopedic Surgeons Course), Monterey, California.                    |
| March 1969    | “Medical Neurology”, (Univ. California Course), San Francisco, California  |
| Nov. 1968     | “Current Concepts in Schizophrenia”, (Univ. California Course), Mendocino, California.   |

## **PUBLICATIONS**

## **BOOKS AND BOOK CHAPTERS**

- Fessel, W.J.: Hyperuricemia. To Treat or not to treat? In “Gout. A Clinical Comprehensive”, Edited by A. Gutman, 1971.
- Fessel, W.J.: Significance of Hyperuricemia, N. CC-85, 1974, prepared for Commission on Continuing Education, American Society of Clinical Pathologists.
- Fessel, W.J.: Rheumatology for Clinicians. Stratton Intercontinental Med. Book Publishing Corp., N.Y., 1975. (Pp 306).
- Contributor, Merck Manual, 13<sup>th</sup> Edition, 1977.

## EDITORIALS

- Fessel, W.J. (Invited Editorial). Leukocytes in Schizophrenia. J.A.M.A., 187:226,1964.
- Fessel, W.J. (Invited Editorial): “Psychosis: Biological or Psychological?” J.A.M.A., 186: 509-510,1963.
- Fessel, W.J. (Invited Editorial) Hypophosphatemia and the clinician. Heart and Lung, 6: 429-430, 1977.
- Fessel, W.J. (Invited Commentary): Early symptoms of HIV infection; implications for therapy. Amer J Epidemiol, 1995;141:405-6.
- Fessel, W.J. Team-Up to help the homeless (editorial). Christian Science Monitor 81:18, 198.
- Fessel W.J. and Hurley L.B. (Invited Editorial). Incidence of pancreatitis in HIV-infected patients: Comment on findings in EuroSIDA cohort. AIDS 2008, 22:145–147.
- Fessel WJ. Editorial Comment: Impaired neurocognition in HIV-infected patients: antecedents and treatment. AIDS 2009;23:1731-1733.

## JOURNAL ARTICLES

1. Shannon, F.T., Fessel, W.J., and Bywaters, E.G.L.: Intracutaneous Congo Red Test in Rheumatoid Arthritis. Annals of Rheumatic Diseases, 16: 225-229, (June) 1957.
2. Epstein, W.V., Engleman, E.P., and Fessel, W.J.: Immunologic Studies in the Connective Tissue Diseases. Clinical Research, 7: 121-122, (January) 1959.
3. Fessel, W.J.: Nucleoprotein Latex Agglutination Tests in Connective Tissue Disease. Annals Rheumatic Diseases, 18: 225-228 (September) 1959.
4. Fessel, W.J.: Nucleohistone and the LE Factor. Lancet, 2: 297 (September) 1959.
5. Fessel, W.J. and Solomon, G.F.: Psychosis and Systemic Lupus Erythematosus. (A review of the

- literature and case reports). California Medicine, 92: 266-270 (April) 1960.
6. Fessel, W.J.: Serum Protein Abnormalities in Psychosis: Serological, Medical and Psychiatric Correlations. J. Nerv. Ment. Dis., 132: 89-90 (January) 1961.
  7. Fessel, W.J.: Disturbed Serum Proteins in Chronic Psychosis: Serological, Medical and Psychiatric Correlations. Arch. Gen. Psychiat., 4: 154-159 (February) 1961.
  8. Fessel, W.J.: Serum Substances Behaving Like Rheumatoid Factor and Lupus Factor in Chronic Psychosis. Arthritis and Rheumatism, 4: 111 (February) 1961.
  9. Grunbaum, B.W., Fessel, W.J., and Piel, C.: Densitometric Evaluation of Microelectrophoretic Serum Protein Patterns on Cellulose Acetate Membranes. Analyt. Chem., 33: 860-861 (June) 1961.
  10. Fessel, W.J. and Grunbaum, B.W.: Electrophoretic and Analytical Ultracentrifuge Studies in Sera of Psychotic Patients: Elevation of Gamma Globulins and Macroglobulins and Splitting of Alpha - 2 Globulins. Ann. Int. Med., 54: 1134-1145 (June) 1961.
  11. Fessel, W.J.: Blood Proteins in Functional Psychosis: A review of the literature and unifying hypothesis. Arch. Gen. Psychiat., 6: 132-148 (February) 1962.
  12. Fessel, W.J.: Macroglobulin Elevations in Functional Mental Illness. Nature, 193: 1005 (March 10) 1962.
  13. Fessel, W.J.: Serum Protein Disturbance in Retinitis Pigmentosa: and the Association of Retinitis Pigmentosa with Psychosis. Amer. Journal of Ophthalmology, 53: 640-642 (April) 1962.
  14. Fessel, W.J.: Autoimmunity and Mental Illness. A preliminary report. Arch. Gen. Psychiat., 6: 320-323 (April) 1962.
  15. Fessel, W.J.: Mental Stress, Blood Proteins and the Hypothalamus. Experimental results showing effect of mental stress upon 4S and 19S proteins: Speculation that the functional behavior disturbances may be expressions of a general metabolic disorder. Arch. Gen. Psychiat., 7:427-435 (December) 1962.
  16. Fessel, W.J.: Clinical Analysis of 142 Cases with High Molecular Weight Serum Proteins. Acta. Med. Scand., 173 (Suppl. 391): 1-32, 1962.
  17. Fessel, W.J.: Multiple Antigenic Determinants of Macroglobulins. Proc. Soc. Exper. Biol. And Med., 113: 446, 1963.
  18. Fessel, W.J.: Loss of Immunological Reactivity of an Alpha-2 Globulin after Prolonged Freezing of Serum. Nature, 197: 1307, 1963.
  19. Fessel, W.J.: The Anti-Brain Factor in Psychiatric Patients' Sera I. Further Studies with a Hemagglutination Technique. Arch. Gen. Psychiat., 8: 614-621 (June) 1963.
  20. Kurland, H. and Fessel, W.J.: Distinctive Protein Patterns in Psychosis. Proc. Soc. Exper. Biol. And Med., 113: 249-251 (June) 1963.
  21. Solomon, G.F., Moos, R.H., Stone, G.C., and Fessel, W.J.: Peripheral Vasoconstriction Induced by Emotional Stress in Rats (Abstract). Arthritis and Rheumatism, 6: 300 (June) 1963.
  22. Solomon, G.F., Moos, R.H., Stone, G.C., and Fessel, W.J.: Peripheral Vasoconstriction Induced by Emotional Stress in Rats. Angiology, 15: 362-365 (August) 1964.
  23. Fessel, W.J. and Hirata-Hibi, M.: Abnormal Leukocytes in Schizophrenia. Arch. Gen. Psychiat., 9: 601-613 (January) 1964.
  24. Fessel, W.J. and Kurland, H.: Serological Distinction between Schizophrenia and Manic Depression. Arch. Int. Med., 113: 669-671 (May) 1964.
  25. Kurland, H., Fessel, W.J., and Cutler, R.P.: Clinical Aspects of a Serologic Study of Psychoses.

- Arch. Gen. Psychiat., 10: 262-266 (March) 1964.
26. Hirata-Hibi, M. and Fessel, W.J.: The Bone Marrow in Schizophrenia. Arch. Gen. Psychiat., 10: 414-419 (April) 1964.
  27. Fessel, W.J. and Forsythe, R.: Hypothalamic Role in Gamma Globulin Levels. Paper Read at the Third Pan American Congress on Rheumatic Diseases, October 15-19, 1963, Santiago, Chile.
  28. Fessel, W.J.: Dysproteinemias of Functional Psychoses; their Significance and Possible Cellular Origin. Paper read at American Psychiatric Association Meeting, San Francisco, 1963.
  29. Fessel, W.J.: How Do the Multiple Psychobiological Determinants of Schizophrenia Interact? Arch. Gen. Psychiat., 11: 1- 18 1964.
  30. Fessel, W.J., Feichtmair, T.V., and Spector, D.S.: What is the Albumin Level? Arch. Int. Med., 114: 547 (October) 1964.
  31. Fessel, W.J.: Dextran Turbidity: Distress Phase Reactant. Nature, 205: 771-773 (February 20) 1965.
  32. Fessel, W.J.: Odd Men Out. Individuals with Extreme Values. Arch. Int. Med., 115: 736-737 (June) 1965.
  33. Solomon, G.F., Moos, R.H., Fessel, W.J., and Morgan E.E.: Globulins and Behavior in Schizophrenia. Int. J. Neuropsychiat., 2: 20-26, 1966.
  34. Fessel, W.J., Hirata-Hibi, M. and Shapiro, I.: Genetic and Stress Factors Affecting the Abnormal Lymphocyte in Schizophrenia. J. Psychiat. Res., 3: 275-283, 1965.
  35. Fessel, W.J. and Pearson, C.M.: Polymyalgia Rheumatic and Blindness. New Eng. J. Med., 276: 1403-1405 (June 22) 1967.
  36. Haygood, T.H., Fessel, W.J., and Strange, D.A.: Atheromatous Microembolism Simulating Polymyositis. J.A.M.A., 208: 135-137 (February 7) 1968.
  37. Fessel, W.J.: The Myopathy of Hypothyroidism. Annals of Rheumatic Diseases, 27: 590-596 (November) 1968.
  38. Fessel, W.J. and Raas, M.A.: Auto-immunity in the Pathogenesis of Muscle Disease. Neurology, 18: 1137, 1968.
  39. Fessel, W.J., Taylor, J.A., and Johnson, E.S.: Detection of Muscle Weakness by Simple, Quantitative, Clinical Test Procedures that Distinguish Myopathic from Non-Myopathic Subjects. Excerpta Medica, 186 (I.C.S.) 64, 1969.
  40. Fessel, W.J.: Polymyalgia Rheumatica, Temporal Arteritis, and Contact with Birds. Lancet, 2: 1249-1250 (Dec 6) 1969.
  41. Fessel, W.J. and Ilkin, J.S.: Myalgia and Bird-Keeping. Lancet, 1: 1403-1404 (June 27) 1970.
  42. Fessel, W.J.: Pathogenesis of Diabetic and Alcoholic Neuropathy. New England J Med., 284: 729 (Apr 1) 1971.
  43. Fessel, W.J.: Fat Disorders and Peripheral Neuropathy. Brain, 94: 531-540, 1971.
  44. Fessel, W.J. and Van Brunt, E.E.: Assessing the Quality of Medical Care. New England J Med., 286: 134-138, 1972.
  45. Fessel, W.J.: Role of Infection in Polymyalgia Rheumatic and Giant Cell Arteritis (Abstract). 7<sup>th</sup> European Congress of Rheumatology, 1971.
  46. Fessel, W.J.: Immunologic Reactivity in Hyperuricemia. New England J Med., 286: 1218, 1972.
  47. Fessel, W.J.: Hyperuricemia in Health and Disease. Seminars in Arthritis and Rheumatism, 1: 275-299, 1972.



48. Trevor, R.P., Sondheimer, F.K., Fessel, W.J., and Wolpert, S.M.: Angiographic Demonstration of Major Cerebral Vessel Occlusion in Systemic Lupus Erythematosus. Neuroradiology, 4: 202-207, 1972.
49. Fessel, W.J., Siegelau, A.B., and Johnson, E.S.: Correlates and Consequences of Asymptomatic Hyperuricemia. Arch Intern Med., 132: 44-54, 1973.
50. Fessel, W.J.: Remote Effects of Benign Neoplasms. New England J Med., 288: 323, 1973.
51. Fessel, W.J.: Iperuricemia in condizioni normali e patologiche. Aggiornamenti in Reumatologia, 3: 1-38, 1973.
52. Fessel, W.J.: Muscle Diseases in Rheumatology. Seminars in Arthritis and Rheumatism, 3: 127-154, 1973.
53. Moser, C.M. and Fessel, W.J.: Rheumatic Manifestations of Hypophosphatemia. Archives of Internal Medicine, 134: 674-678, 1974.
54. Fessel, W.J.: Systemic Lupus Erythematosus in the Community: Incidence, Prevalence, Outcome, and First Symptoms. The High Prevalence in Black Women. Arch Intern Med., 134: 1027-1035, 1974.
55. Wagner, L.P. and Fessel, W.J.: HL-A27 (W27) absent in gonococcal arthritis. Lancet, 1: 1094, 1975.
56. Fessel, W.J. and Barr, G.D: Uric acid, lean body weight, and creatinine interactions: results from regression analysis of 78 variables. Semin. Arthritis Rheum., 7: 115-121, 1977.
57. Fessel, W.J.: Mixed connective tissue disease. New England J Med., 296:450, 1977.
58. Fessel, W.J.: Scleroderma and welding. New England J Med., 296: 1537, 1977.
59. Fessel, W.J.: Reversal of azotemia in lupus nephritis by megadose corticosteroid therapy. Arthritis Rheum., 20: 1564-1565, 1977.
60. Fessel, W.J.: ANA-negative systemic lupus erythematosus. American Journal of Medicine., 64: 80-86, 1978. Fessel, W.J.: Distinguishing gout from other kinds of arthritis. Postgraduate Med., 63: 134-138, 1978.
61. Fessel, W.J.: Systemic lupus erythematosus as seen in primary care. Postgraduate Med., 65: 113-124, 1979.
62. Fessel, W.J.: Renal outcomes of gout and hyperuricemia. American Journal of Medicine, 67: 74-82, 1979.
63. Fessel, W.J.: High uric acid as an indicator of cardiovascular disease. American Journal of Medicine., 68: 401-404, 1980.
64. Fessel, W.J.: Megadose corticosteroid therapy in systemic lupus erythematosus. J Rheumatol, 7: 486-500. 1980.
65. Herbert, D.A. and Fessel, W.J.: Idiopathic hypertrophic osteoarthropathy (pachydermoperiostosis). West J Med., 134: 354-357, 1981.
66. Fessel, W.J.: Strategic aspects of prescription writing. Postgraduate Med., 70: 30-37, 1981.
67. Fessel, W.J.: The nature of illness and diagnosis. American Journal of Medicine., 75: 555-560, 1983.
68. Fessel, W.J.: Epidemiology of S.L.E. Rheum. Dis. Clin. N. Amer., 14-23, 1988.
69. Fessel, W.J. Megestrol acetate and hyperpnea. Annals of Internal Medicine 110:1034-1035, 1989.
70. Fessel, W.J. Nonsteroidal anti-inflammatory drugs diminish CD4+ and CD8+ lymphocyte levels in some HIV-positive patients. (Abstract) J Acquired Immune Defic Syndr, 1991; 4:348-9

71. Fessel, W.J. CD8+ lymphocytes restrain progression of AIDS. presented in abstract at the 7<sup>th</sup> International Congress on AIDS, Florence, Italy, June 1991.
72. Fessel, W.J. Cryptococcal meningitis after unusual exposure to birds. New England Journal of Medicine, 1993; 328:1354.
73. Rasmussen, L., et al (including Fessel, W.J.). Deficiency in antibody response to human cytomegalovirus glycoprotein gH in human immunodeficiency virus-infected patients at risk for cytomegalovirus retinitis. J Infect Dis, 1994; 170:673-7.
74. Rasmussen, L., Morris, S., Zipeto, D., Fessel, W.J., et al. Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. J Infect Dis, 1995; 171:177-182.
75. Simon, D.M., et al (including Fessel, W.J.). Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea. Gastroenterology, 1995; 108:1753-1760.
76. Suzuki, Y., Wong, S-W., Grumet, R.L., Fessel, W.J., et al. Evidence for genetic regulation of susceptibility to toxoplasmic encephalitis in AIDS patients. J Infect Dis, (1996); 173:265-8.
77. Mildvan, D., et al (including Fessel, W.J.). Synergy and tolerability of zidovudine and interferon - alpha in patients with symptomatic HIV-1 infection: ACTG068. Antiviral Therapy, 1996; 1:77-88.
78. Fessel, W.J. Early treatment of HIV infection (letter). New Engl J Med, 1995; 333:1782.
79. Fessel, W.J. Viral load and response to treatment of HIV (letter). New Engl J Med, 1996; 334:1671.
80. Fessel, W.J. A critique of plasma HIV RNA as preferred target for therapy. Clin Infect Dis, 1997; 24:116-122.
81. Chaisson, R.E., Keiser, P., Pierce, M., Fessel, W.J., et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of mycobacterium avium complex disease in patients with human immunodeficiency virus infection. AIDS, 1998.
82. Oldfield, E.C.<sup>3rd</sup>, Fessel, W.J., Dunne, M.W., et al. Once weekly azithromycin therapy for prevention of mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial. Clin Infect Dis. 1998;26:611-619.
83. Fessel, W.J., Follansbee, S., Hurley, L., Klein D. Does use of potent antiretroviral therapy differ by health care setting? J.A.M.A. 1999;281:1696-1697.
84. Saag, M S., Fessel, W.J., Kaufman, C.A., et al. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. AIDS Research and Human Retroviruses, 1999;15:1413-1417.
85. Saag MS, Cloud GA, Graybill JR, Sobel JD, Tuazon CU, Johnson PC, Fessel WJ, Moskovitz BL, Wiesinger B, Cosmatos D, Riser L, Thomas C, Hafner R, Dismukes WE. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis. 1999;28:291-296.
86. Fessel, W.J., Krowka, J., Sheperd, H., et al. Dissociation of immunologic and virologic responses to highly active antiretroviral therapy. J.AIDS, 2000;23: 314-320.
87. Fessel, W.J., Follansbee, S.E., Young, T.P. Salvage therapy and formulation of highly active antiretroviral therapy. J.AIDS, 2000;24:194-195.
88. Dunne, M., Fessel, J., Kumar, P. et al. A randomized double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated mycobacterium avium infection in patients

- with human immunodeficiency virus. *Clin Infect Dis*. 2000;31:1245-1252.
89. Fessel, W.J. Commentary. "Acute rheumatic fever in adults." *The Permanente Journal*. 2000;4(4).
  90. Kaplan, G. et al (including Fessel, W.J.). Thalidomide for the treatment of AIDS-associated wasting. *AIDS Res Hum Retrovir* 2000;16:1345-1355.
  91. Haas, D.W., Fessel, W.J., Delapenha, R.A., et al. Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse transcriptase inhibitor experience: a randomized, double blind, placebo-controlled trial. *J Infect Dis*, 2001;183:392-400.
  92. Kantor R, Fessel, WJ, Zolopa AR, et al. Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy.. *Antimicrob Chemo* 2002; 46: 1086-1092.
  93. Fessel WJ, Follansbee SE, Rego J. Low HDL cholesterol in HIV-infected patients with lipodystrophic fat expansions: possible implications for pathogenesis of the fat redistribution syndrome. *AIDS* 2002,16:1785-1789.
  94. Fessel WJ, Hurley LB. Is HIV sequestered in bone? Possible implications of virological and immunological findings in some HIV-infected patients with bone disease. *AIDS* 2003; 17(2): 255-7.
  95. Gonzales MJ, Wu TD, .....Fessel WJ, Shafer RW. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. *AIDS* 2003; 17: 791-799.
  96. Wu TD,.....Fessel WJ, Shafer RW. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. *J. Virol*. 2003; 77: 4836 – 4847.
  97. Kantor R, .....Fessel WJ. Evolution of resistance to drugs in HIV-1 infected persons failing antiretroviral therapy. *AIDS* 2004;18:1503-1511.
  98. Fessel WJ. New approach to an HIV/AIDS vaccine: converting HIV into a benign infection. *Med Hypoth* 2005;64:261-3.
  99. Friedman GD, Fessel WJ, Udaltsova NJ, Hurley LB. Cryptococcosis: the 1981-2000 epidemic. *Mycoses* 2005;48:122-125.
  100. Rhee S-Y, Fessel WJ, et al. Protease and reverse transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. *J Infect Dis* 2005;192:456-465.
  101. Mitsuya Y, Winters MA, Fessel WJ et al. N88D Facilitates the Co-Occurrence of D30N and L90M and the Development of Multidrug Resistance in HIV-1 Protease Following Nelfinavir Treatment Failure. *AIDS Res Hum Retroviruses*. 2006; 22: 12: 1300-5.
  102. Mitsuya Y, Winters MA, Fessel WJ et al. HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/ml. *J Acquir Immune Defic Syndr*. 2006;43:56-59.
  103. Altmann A, et al with Fessel W.J. Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance. *Antiviral Therapy*, 2007;12:169-178.
  104. Mitsuya Y, Liu TF, Rhee S-Y, Fessel WJ, Shafer RW. Prevalence of darunavir-associated resistance mutations: patterns of occurrence and association with past treatment. *J Infect Dis*. 2007;196:1177 – 1179.
  105. Peterson, M L, Wang Y, vanderLaan M, Rhee S-Y, Shafer SW, Fessel WJ. Virologic efficacy of boosted double versus boosted single protease inhibitor therapy. *AIDS* 2007;21:1547-5554.

106. Falutz J, .....Fessel J, Grinspoon S. Effects of TH9507, a growth hormone releasing factor analog, on HIV-associated abdominal fat accumulation. *N Engl J Med* 2007 Dec 6; 357:2359.
107. Becker.....Fessel J...et al. Quality of life and disability in patients with treatment failure gout. *J Rheumatol* 2008 In Press.
108. Bembom, O, with Fes Kantor R, .....Fessel WJ. Evolution of resistance to drugs in HIV-1 infected persons failing antiretroviral therapy. *AIDS* 2004;18:1503-1511.
109. Fessel WJ. New approach to an HIV/AIDS vaccine: converting HIV into a benign infection. *Med Hypoth* 2005;64:261-3.
110. Friedman GD, Fessel WJ, Udaltsova NJ, Hurley LB. Cryptococcosis: the 1981-2000 epidemic. *Mycoses* 2005;48:122-125.
111. Rhee S-Y, Fessel WJ, et al. Protease and reverse transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. *J Infect Dis* 2005;192:456-465.
112. Mitsuya Y, Winters MA, Fessel WJ et al. N88D Facilitates the Co-Occurrence of D30N and L90M and the Development of Multidrug Resistance in HIV-1 Protease Following Nelfinavir Treatment Failure. *AIDS Res Hum Retroviruses*. 2006; 22: 12: 1300-5.
113. Mitsuya Y, Winters MA, Fessel WJ et al. HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/ml. *J Acquir Immune Defic Syndr*. 2006;43:56-59.
114. Altmann A, et al with Fessel W.J. Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance. *Antiviral Therapy*, 2007;12:169-178.
115. Mitsuya Y, Liu TF, Rhee S-Y, Fessel WJ, Shafer RW. Prevalence of darunavir-associated resistance mutations: patterns of occurrence and association with past treatment. *J Infect Dis*. 2007;196:1177 – 1179.
116. Peterson, M L, Wang Y, vanderLaan M, Rhee S-Y, Shafer SW, Fessel WJ. Virologic efficacy of boosted double versus boosted single protease inhibitor therapy. *AIDS* 2007;21:1547-5554.
117. Falutz J, .....Fessel J, Grinspoon S. Effects of TH9507, a growth hormone releasing factor analog, on HIV-associated abdominal fat accumulation. *N Engl J Med* 2007 Dec 6; 357:2359.
118. Bembom, O, with Fessel WJ et al. Biomarker discovery using targeted maximum likelihood estimation: Application to the treatment of antiretroviral resistant HIV infection. *Statistics in Medicine*. *Statist. Med.* (2008). Published online in Wiley InterScience.
119. Mitsuya Y, .....Fessel WJ, Shafer RW. Minority HIV-1 variants in antiretroviral naive persons with reverse transcriptase codon 215 revertant mutations. *J Virol*. 2008;82:10747-10755.
120. Falutz, J, ..... Fessel J, Grinspoon S. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. *AIDS* 2008;22:1719-1728.
121. Altmann A, et al with Fessel W.J. Predicting the response to combination antiretroviral therapy: retrospective validation of geno2pheno-THEO on a large clinical database. *J Infect Dis*. 2009;199:999-1006.

122. Altmann A, et al with Fessel W.J. Advantages of predicted phenotypes and statistical learning models in inferring virological response to antiretroviral therapy from HIV genotype. *Antiviral Therapy*. 2009;14:273-83.
123. Rhee S-Y, Fessel WJ, et al. Predictive value of HIV-1 genotypic resistance test interpretation algorithms. *J Infect Dis*. 2009;200:453-463.
124. Reuman EC, Bachmann MH, Varghese V, Fessel WJ, Shafer RW. Panel of Prototypical Raltegravir-Resistant Infectious Molecular Clones in a Novel Integrase-Deleted Cloning Vector. *Antimicrob Chemother*. 2010; 54:Feb.
125. Varghese V, Wang E, Babrzadeh F, Bachmann MH, Shahriar R, Liu T, Mappala SJM, Baback Gharizadeh B, Fessel WJ, Katzenstein D, Kassaye S, Shafer RW. Nucleic Acid Template and the Risk of a PCR-Induced HIV-1 Drug Resistance Mutation. *PLoS One*. 2010 Jun 7;5(6).
126. Varghese V, Liu TF, Rhee S-Y, Libiran P, Trevino C, Fessel WJ, Shafer RW. HIV-1 integrase sequence variability in antiretroviral naive patients and in triple-class experienced patients subsequently treated with raltegravir. *AIDS Res and Human Retrovir* 2010; 6:1323-6.
127. Rhee SY, Taylor J, Fessel WJ, Kaufman D, Towner W, Troia P, Ruane P, Hellinger J, Shirvani V, Zolopa A, Shafer RW. [HIV-1 protease mutations and protease inhibitor cross-resistance](#). *Antimicrob Agents Chemother*. 2010 Oct; 54(10):4253-61.
128. Varghese VP, Shahriar R, Rhee S-Y, Liu T, Simen BB, Egholm M, Hanczaruk B, Blake MA, Gharizadeh B, Babrzadeh F, Bachmann MH, Fessel WJ, Shafer RW. Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors. Submitted for publication.
129. Fessel WJ, Chau Q, and Leong D. Association of osteonecrosis and osteoporosis in HIV-1-infected patients. *AIDS* 2011; 25: 1877-1880.
130. Fessel WJ, Chau Q, and Leong D. Association of osteonecrosis and peripheral neuropathy in HIV-1 infected patients: possible roles of nerve growth factor and vascular endothelial growth factor. *AIDS* 2011; 25:2305-2306.
131. Fessel, WJ, Anderson B, Follansbee SE, Winters MA, Lewis S, Weinheimer S, Petropoulos CJ, Robert W. Shafer RW. The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment. *Antiviral Res*. 2011; 92:484-7.
132. Rhee SY, Blanco JL, Liu TF, Pere I, Kaiser R, Zazzi M, Incardona F, Towner W, Gatell J, De Luca A, Fessel WJ, Shafer RW. Standardized representation, visualization and searchable repository of antiretroviral treatment-change episodes. *AIDS Res Ther*. 2012;9(1):13.
133. Fessel WJ. There are many potential medical therapies for atraumatic osteonecrosis. (Review). *Rheumatology (Oxford)*. 2013;52:235-241.
134. Babrzadeh F, Varghese V, Pacold M, Liu TF, Nyrén P, Schiffer C, Fessel WJ, Shafer RW. Collinearity of Protease Mutations in HIV-1 Samples with High-Level Protease Inhibitor Class Resistance. *J Antimicrob Chemother*. 2013;68:414-418.
135. Varghese V, Mitsuya Y, Fessel WJ, et al. Prototypical Recombinant Multi-Protease Inhibitor Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type-1. *J Antimicrob Chemother*. 2013;57:4290-4299.
136. Sulkowski M, with Fessel WJ et al. All oral therapy with Sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2 and 3 infection in patients with HIV coinfection. *JAMA* 2014;312:353-361.
137. Clutter DS, Fessel WJ, Rhee SY, Hurley LB, Klein DB, Ioannidis JP, Silverberg MJ, Shafer RW. Response to Therapy in Antiretroviral Therapy–Naive Patients With Isolated Nonnucleoside Reverse Transcriptase Inhibitor–Associated Transmitted Drug Resistance. *J AIDS* 2016;72:171-176.
138. Fessel J. Alzheimer’s disease: a way forward? Combination treatment for the mitochondriopathy. *Alzheimer's & Dementia*. 2016 Jul 1;12(7):P822-3..

139. Clutter DS, Zhou S, Varghese V, Rhee SY, Pinsky BA, Fessel WJ, Klein DB, Spielvogel E, Holmes SP, Hurley LB, Silverberg MJ. Prevalence of drug-resistant minority variants in untreated HIV-1-infected individuals with and without transmitted drug resistance by Sanger sequencing. *J Infect Dis.* 2017(Jul 25).
140. Fessel WJ. Concordance of Several Subcellular Interactions Initiates Alzheimer's Dementia: Their Reversal Requires Combination Treatment. *Amer J Alzheimer's Dis Other Dementias.* 2017;32:166-181.
141. Fessel J. Amyloid is essential but insufficient for Alzheimer causation: addition of subcellular cofactors is required for dementia. *International Journal of Geriatric Psychiatry.* 2018;33(1):e14-21.
142. Emu B, Fessel J, et al. Phase 3 study of ibalizumab for multi-drug resistant HIV-1. *New Engl. J Med.* 2018;379:645-654.
143. Fessel J. Alzheimer's disease Combination treatment for Alzheimer's disease. *Neurobiology of Aging.* 2018;63:165.
144. Fessel J. Ineffective levels of transforming growth factors and their receptor account for old age being a risk factor for Alzheimer's disease. *Alzheimers & Dement: Translational Research & Clinical Interventions.* 2019;5:899-905.
145. Fessel J. [If ineffective levels of transforming growth factors and their receptor account for old age being a risk factor for Alzheimer's disease, then increasing TGFBR2 might be therapeutic.](#) DOI: 10.1002/trc2.12019. Published online May 2020.
146. Fessel J. Prevention of Alzheimer's disease by treating mild cognitive impairment with combinations chosen from eight available drugs. *Alzheimer's & Dementia: Translational Research & Clinical Interventions.* 2019;5:780-788.
147. Fessel J. The paradox of opposite directions of gene expressions in MCI and AD suggests possible therapy to prevent progression of MCI to AD. *Alzheimers & Dement.* 2020;6(1).
148. Fessel J. The potential for one drug, administered at the earliest preclinical stage, to prevent the subsequent decline of cognition that eventuates in dementia. *Alzheimers & Dement.* Published on-line Sept 2020. DOI:10.1002/trc2.12084.
149. Fessel J. Caveolae, CD109, and endothelial cells as targets for treating Alzheimer's disease. *Alzheimer's & Dementia: Translational Research & Clinical Interventions.* 2020;6(1):e12066.
150. Fessel J. A vaccine to prevent initial loss of cognition and eventual Alzheimer's disease in elderly persons. *Alzheimer's & Dementia: Translational Research & Clinical Interventions.* 2021;7(1):e12126.
151. Fessel J. In cognitively normal elderly persons, one thiamine tablet of 100 mg, taken daily, may prevent subsequent cognitive loss that eventuates in Alzheimer's dementia. In Press.
152. Fessel J. Does synaptic hypometabolism or synaptic dysfunction, originate cognitive loss? Analysis of the evidence. *Alzheimer's & Dementia: Translational Research & Clinical Interventions.* 2021;7(1):e12177.
153. Fessel J. [Supplemental thiamine as a practical, potential way to prevent Alzheimer's disease from commencing.](#) *Alzheimer's & Dementia: Translational Research & Clinical Interventions.* 2021 Jan 1;7(1):e12199.
154. Fessel J. Reversing Alzheimer's disease dementia with clemastine, fingolimod, or rolipram, plus anti-amyloid therapy. *Alzheimer's & Dementia: Translational Research & Clinical Interventions.* 2022;8(1):e12242.
155. Fessel J. Abnormal oligodendrocyte function in schizophrenia explains the long latent interval in some patients. *Transl Psychiatry* 2022 Mar 25;12(1):120. doi: 10.1038/s41398-022-01879-0.

156. Fessel J. Prevention of Alzheimer's dementia may be within reach. *Clinical and Translational Discovery*. 2022 Jun 1;2(2):e44.s
157. Fessel J. Fluoxetine plus lithium for treatment of mental health impairment in Long Covid. *Discover Mental Health*. 2023 Dec;3(1):1-2
158. Fessel J. Formulating treatment of major psychiatric disorders: algorithm targets the dominantly affected brain cell-types. *Discover Mental Health*. 2023 Dec;3(1):1-8.
159. Fessel J. Supplementary pharmacotherapy for the behavioral abnormalities caused by stressors in humans, Focused on post-traumatic stress disorder (PTSD). *Journal of Clinical Medicine*. 2023 Feb 20;12(4):1680-1699.
160. Fessel J. Cure of Alzheimer's Dementia Requires Addressing All of the Affected Brain Cell Types. *Journal of Clinical Medicine*. 2023 Mar 4;12(5):2049.
161. Fessel J. Cure of Alzheimer's Dementia in Many Patients by Using Intranasal Insulin to Augment an Inadequate Counter-Reaction, Edaravone to Scavenge ROS, and 1 or 2 Other Drugs to Address Affected Brain Cells. *Journal of Clinical Medicine*. 2023 Apr 27;12(9):3151.
162. Fessel J. The several ways to authentically cure Alzheimer's dementia. *Ageing Research Reviews* 2023 In Press.